Alveron Pharma is developing a unique coagulation

platform technology with the world's first

cyclodextrin-based anticoagulant reversal drug 

Alveron Pharma's proprietary cyclodextrin-based compounds accelerate, but not initiate, coagulation via a unique mechanism. These compounds can therefore be used as systemic anti-bleeding agents, and our lead program is focused on developing a truly universal anticoagulant reversal agent.

Learn more